References

Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high locally advanced, non-metastatic colorectal cancer

10.1093/bjs/znac050 · 2022 · External reference

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

10.1056/nejmoa2201445 · 2022 · External reference

Neoadjuvant relatlimab and nivolumab in resectable melanoma

10.1038/s41586-022-05368-8 · 2022 · External reference

Pembrolizumab in Early Triple-Negative Breast Cancer

10.1056/nejmc2203316 · 2022 · External reference

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

10.1038/s41591-020-01224-2 · 2021 · External reference

Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma

10.1186/s12885-018-4829-0 · 2018 · External reference

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

10.1038/s41586-021-03642-9 · 2021 · External reference

LAG-3: from molecular functions to clinical applications

10.1136/jitc-2020-001014 · 2020 · External reference

CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling

1998 · External reference

The effect of immune microenvironment on the progression and prognosis of colorectal cancer

10.1007/s12032-014-0082-9 · 2014 · External reference

LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma

10.1080/2162402x.2016.1239005 · 2016 · External reference

Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer

10.1158/1078-0432.ccr-14-2926 · 2015 · External reference

Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction

10.1016/j.jim.2018.02.003 · 2018 · External reference

Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma

2013 · External reference

LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8 + T cell signaling and dampen antitumor immunity in a murine ovarian cancer model

10.18632/oncotarget.4751 · 2015 · External reference

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

10.1056/nejmoa2109970 · 2022 · External reference

Surgical outcomes of patients with resectable non-small-cell lung cancer receiving neoadjuvant immunotherapy with nivolumab plus relatlimab or nivolumab: Findings from the prospective, randomized, multicentric phase II study NEOpredict-Lung

10.1200/jco.2023.41.16_suppl.8500 · 2023 · External reference

Anti-TIGIT therapies for solid tumors: a systematic review

10.1016/j.esmoop.2023.101184 · 2023 · External reference

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

10.1038/ni.1674 · 2009 · External reference

Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses

10.1016/j.immuni.2014.02.012 · 2014 · External reference

The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function

10.1016/j.ccell.2014.10.018 · 2014 · External reference

Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation

10.3389/fimmu.2019.01179 · 2019 · External reference

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

10.1186/s40425-016-0191-4 · 2016 · External reference

Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck

10.1158/1078-0432.ccr-21-2635 · 2022 · External reference

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

10.1038/s41586-023-06063-y · 2023 · External reference

Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial

10.1200/jco.2023.41.17_suppl.lba9503 · 2023 · External reference

Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial

10.1001/jamaoncol.2022.5370 · 2023 · External reference

development of peptide-based vaccines for cancer

10.1155/2022/9749363 · 2022 · External reference

Abstract CT064: phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy

10.1158/1538-7445.am2023-ct064 · 2023 · External reference

Abstract LB199: A personalized neoantigen vaccine is well tolerated and induces specific T-cell immune response in patients with resected melanoma

10.1158/1538-7445.am2023-lb199 · 2023 · External reference

Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer

10.1200/jco.2003.02.122 · 2003 · External reference

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute

10.1186/s40425-017-0279-5 · 2017 · External reference

Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells

10.1158/1078-0432.ccr-21-4239 · 2022 · External reference

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

10.1200/jco.22.00343 · 2023 · External reference

B cells are associated with survival and immunotherapy response in sarcoma

10.1038/s41586-019-1906-8 · 2020 · External reference

B cells and tertiary lymphoid structures promote immunotherapy response

10.1038/s41586-019-1922-8 · 2020 · External reference

Tertiary lymphoid structures improve immunotherapy and survival in melanoma

10.1038/s41586-019-1914-8 · 2020 · External reference

Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer

10.1016/j.immuni.2022.02.001 · 2022 · External reference

Esophagogastric Cancers: Integrating Immunotherapy Therapy Into Current Practice

10.1200/jco.21.02500 · 2022 · External reference

The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy

10.1016/j.ccell.2018.03.015 · 2018 · External reference

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

10.1126/science.abb5920 · 2021 · External reference

Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients

10.1126/science.abf3363 · 2021 · External reference

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

10.1016/s1470-2045(22)00518-6 · 2022 · External reference

IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC)

10.1200/jco.2021.39.15_suppl.8500 · 2021 · External reference

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

10.1056/nejmoa2106391 · 2021 · External reference

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

10.1056/nejmoa2034442 · 2021 · External reference

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

10.1016/s0140-6736(22)00562-1 · 2022 · External reference

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

10.1056/nejmoa1709030 · 2017 · External reference

Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K)

10.25251/skin.7.supp.163 · 2023 · External reference

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

10.1016/s0140-6736(22)01654-3 · 2022 · External reference

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

10.1158/1078-0432.ccr-22-3145 · 2023 · External reference

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

10.1056/nejmoa1802357 · 2018 · External reference

804P Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial

10.1016/j.annonc.2022.07.930 · 2022 · External reference

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

10.1056/nejmoa2032125 · 2021 · External reference

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

10.1056/nejmoa2202170 · 2022 · External reference

Pembrolizumab for Early Triple-Negative Breast Cancer

10.1056/nejmoa1910549 · 2020 · External reference

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

10.1056/nejmoa2211437 · 2023 · External reference

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials

10.1016/j.annonc.2023.01.004 · 2023 · External reference

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

10.1038/s41591-022-01851-x · 2022 · External reference

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

10.1038/s41591-020-0805-8 · 2020 · External reference

LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study

10.1016/j.annonc.2022.08.016 · 2022 · External reference